Literature DB >> 17584757

Plasma urate and risk of Parkinson's disease.

M G Weisskopf1, E O'Reilly, H Chen, M A Schwarzschild, A Ascherio.   

Abstract

Oxidative stress contributes to dopaminergic neuron degeneration in Parkinson's disease. Urate, a potent antioxidant, could be neuroprotective. To determine whether higher plasma concentrations of urate predict a reduced risk of Parkinson's disease, the authors conducted a nested case-control study among participants in the Health Professionals Follow-up Study, a cohort comprising over 18,000 men who provided blood samples in 1993-1995. Eighty-four incident cases of Parkinson's disease were diagnosed through 2000, and each was randomly matched to two controls by year of birth, race, and time of blood collection. Rate ratios of Parkinson's disease according to quartile of uricemia were estimated by use of conditional logistic regression. The mean urate concentration was 5.7 mg/dl among cases and 6.1 mg/dl among controls (p = 0.01). After adjustment for age, smoking, and caffeine, the rate ratio of Parkinson's disease for the highest quartile of uricemia compared with the lowest was 0.43 (95% confidence interval: 0.18, 1.02; p(trend) = 0.017). This association was stronger in analyses excluding cases diagnosed within 4 years (median) from blood collection (rate ratio = 0.17, 95% confidence interval: 0.04, 0.69; p(trend) = 0.010). These results suggest that high plasma urate concentrations may decrease the risk of Parkinson's disease, and they raise the possibility that interventions to increase plasma urate may reduce the risk and delay the progression of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584757      PMCID: PMC2391073          DOI: 10.1093/aje/kwm127

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  35 in total

1.  Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite.

Authors:  H Koprowski; S V Spitsin; D C Hooper
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

2.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.

Authors:  Wenzhen Duan; Bruce Ladenheim; Roy G Cutler; Inna I Kruman; Jean Lud Cadet; Mark P Mattson
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

3.  Comparison of uric acid and ascorbic acid in protection against EAE.

Authors:  Sergei V Spitsin; Gwen S Scott; Tatiana Mikheeva; Anna Zborek; Rhonda B Kean; Christine M Brimer; Hilary Koprowski; D Craig Hooper
Journal:  Free Radic Biol Med       Date:  2002-11-15       Impact factor: 7.376

4.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.

Authors:  G T Liberatore; V Jackson-Lewis; S Vukosavic; A S Mandir; M Vila; W G McAuliffe; V L Dawson; T M Dawson; S Przedborski
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

5.  Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction.

Authors:  G Toncev; B Milicic; S Toncev; G Samardzic
Journal:  Eur J Neurol       Date:  2002-05       Impact factor: 6.089

6.  The role of uric acid in protection against peroxynitrite-mediated pathology.

Authors:  G S Scott; D C Hooper
Journal:  Med Hypotheses       Date:  2001-01       Impact factor: 1.538

7.  The central nervous system inflammatory response to neurotropic virus infection is peroxynitrite dependent.

Authors:  D C Hooper; R B Kean; G S Scott; S V Spitsin; T Mikheeva; K Morimoto; M Bette; A M Röhrenbeck; B Dietzschold; E Weihe
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

8.  Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease.

Authors:  A J Hughes; S E Daniel; A J Lees
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

9.  Molecular identification of a renal urate anion exchanger that regulates blood urate levels.

Authors:  Atsushi Enomoto; Hiroaki Kimura; Arthit Chairoungdua; Yasuhiro Shigeta; Promsuk Jutabha; Seok Ho Cha; Makoto Hosoyamada; Michio Takeda; Takashi Sekine; Takashi Igarashi; Hirotaka Matsuo; Yuichi Kikuchi; Takashi Oda; Kimiyoshi Ichida; Tatsuo Hosoya; Kaoru Shimokata; Toshimitsu Niwa; Yoshikatsu Kanai; Hitoshi Endou
Journal:  Nature       Date:  2002-04-14       Impact factor: 49.962

10.  A reassessment of the peroxynitrite scavenging activity of uric acid.

Authors:  M Whiteman; U Ketsawatsakul; B Halliwell
Journal:  Ann N Y Acad Sci       Date:  2002-05       Impact factor: 5.691

View more
  137 in total

Review 1.  Biochemical premotor biomarkers for Parkinson's disease.

Authors:  Brit Mollenhauer; Jing Zhang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

2.  Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Brain Res       Date:  2014-03-26       Impact factor: 3.252

3.  Diethylstilbestrol exposure in utero and depression in women.

Authors:  Eilis J O'Reilly; Fariba Mirzaei; Michele R Forman; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2010-03-23       Impact factor: 4.897

4.  Recreational physical activity and risk of Parkinson's disease.

Authors:  Evan L Thacker; Honglei Chen; Alpa V Patel; Marjorie L McCullough; Eugenia E Calle; Michael J Thun; Michael A Schwarzschild; Alberto Ascherio
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 5.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

Review 7.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

8.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Honglei Chen; Thomas H Mosley; Alvaro Alonso; Xuemei Huang
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

10.  Gout and the risk of Parkinson's disease in Denmark.

Authors:  Eva Schernhammer; Jiaheng Qiu; Lene Wermuth; Christina Funch Lassen; Soren Friis; Beate Ritz
Journal:  Eur J Epidemiol       Date:  2013-03-02       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.